- Home
- ATYR vs PFL Comparison
ATYR vs PFL Comparison
Compare ATYR & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- PFL
- Stock Information
- Founded
- ATYR 2005
- PFL 2003
- Country
- ATYR United States
- PFL United States
- Employees
- ATYR N/A
- PFL N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- PFL Finance Companies
- Sector
- ATYR Health Care
- PFL Finance
- Exchange
- ATYR Nasdaq
- PFL Nasdaq
- Market Cap
- ATYR 330.7M
- PFL 333.6M
- IPO Year
- ATYR 2015
- PFL N/A
- Fundamental
- Price
- ATYR $3.97
- PFL $8.45
- Analyst Decision
- ATYR Strong Buy
- PFL
- Analyst Count
- ATYR 6
- PFL 0
- Target Price
- ATYR $18.60
- PFL N/A
- AVG Volume (30 Days)
- ATYR 2.0M
- PFL 113.7K
- Earning Date
- ATYR 03-13-2025
- PFL 01-01-0001
- Dividend Yield
- ATYR N/A
- PFL 11.53%
- EPS Growth
- ATYR N/A
- PFL N/A
- EPS
- ATYR N/A
- PFL N/A
- Revenue
- ATYR $235,000.00
- PFL N/A
- Revenue This Year
- ATYR $1,387.23
- PFL N/A
- Revenue Next Year
- ATYR $873.22
- PFL N/A
- P/E Ratio
- ATYR N/A
- PFL N/A
- Revenue Growth
- ATYR N/A
- PFL N/A
- 52 Week Low
- ATYR $1.42
- PFL $6.98
- 52 Week High
- ATYR $4.66
- PFL $8.62
- Technical
- Relative Strength Index (RSI)
- ATYR 56.81
- PFL 42.01
- Support Level
- ATYR $2.98
- PFL $8.42
- Resistance Level
- ATYR $3.73
- PFL $8.59
- Average True Range (ATR)
- ATYR 0.40
- PFL 0.05
- MACD
- ATYR 0.04
- PFL -0.01
- Stochastic Oscillator
- ATYR 80.32
- PFL 16.61
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.